Open Payments

KFH - ANTIOCH

Type
Teaching hospital
Where
ANTIOCH, CA
Medicare CCN
050760
Received
$5,633,777 in 241 records, 2020 ($0 general, $5,633,777 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2020Research payment241$5,633,777

By company

CompanyRecordsAmountYears
PFIZER INC.240$5,624,5672020
MEDIVATION LLC.1$9,2102020

By nature of payment

NatureRecordsAmount
Research payment241$5,633,777

Records

DateCompanyAmountNatureFormProductStudyYear
2020-12-29PFIZER INC.$34,099Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-12-29PFIZER INC.$28,343Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-12-25PFIZER INC.$17,057Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-12-19PFIZER INC.$82,943Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-12-18PFIZER INC.$4,332Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-12-16PFIZER INC.$60,193Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-12-16PFIZER INC.$3,962Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VA2020
2020-12-14PFIZER INC.$560Research paymentCash or cash equivalentLORBRENA Drug, ONCOLOGYATOPIC DERMATITIS STANDING COHORT USING A COHORT OF KAISER PERMANENTE NORTHERN CALIFORNIA MEMBERS KPNC2020
2020-12-12PFIZER INC.$38,787Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-12-12PFIZER INC.$30,197Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-12-10PFIZER INC.$148,707Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-12-05PFIZER INC.$41,680Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-12-05PFIZER INC.$41,078Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-12-04PFIZER INC.$9,580Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-12-04PFIZER INC.$1,642Research paymentCash or cash equivalentTALZENNA Drug, ONCOLOGYA PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB IN COMBINATION WITH PHYSICIANS CHOICE OF ENZALUT2020
2020-12-03PFIZER INC.$1,981Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VA2020
2020-12-03PFIZER INC.$1,710Research paymentCash or cash equivalentA PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF066512020
2020-12-03PFIZER INC.$400Research paymentCash or cash equivalentA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V2020
2020-12-03PFIZER INC.$400Research paymentCash or cash equivalentA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V2020
2020-12-02PFIZER INC.$4,969Research paymentCash or cash equivalentA LONGTERM OPEN LABEL EXTENSION STUDY OF PF06651600 FOR THE TREATMENT OF ALOPECIA AREATA2020
2020-12-01PFIZER INC.$32,850Research paymentCash or cash equivalentCLINICAL CHARACTERISTICS TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH HRHER2 BREAST CANCER IN THE UNITED STATES2020
2020-11-28PFIZER INC.$32,128Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-11-28PFIZER INC.$30,611Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-11-26PFIZER INC.$25,901Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-11-21PFIZER INC.$18,690Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-11-21PFIZER INC.$10,656Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VA2020
2020-11-20PFIZER INC.$15,931Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-11-20PFIZER INC.$897Research paymentCash or cash equivalentTALZENNA Drug, ONCOLOGYA PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB IN COMBINATION WITH PHYSICIANS CHOICE OF ENZALUT2020
2020-11-18PFIZER INC.$30,509Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-11-18PFIZER INC.$4,928Research paymentCash or cash equivalentA LONGTERM OPEN LABEL EXTENSION STUDY OF PF06651600 FOR THE TREATMENT OF ALOPECIA AREATA2020
2020-11-18PFIZER INC.$1,619Research paymentCash or cash equivalentA PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF066512020
2020-11-17PFIZER INC.$39,895Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-11-17PFIZER INC.$35,183Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-11-14PFIZER INC.$25,037Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-11-11PFIZER INC.$28,421Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-11-07PFIZER INC.$37,964Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-11-06PFIZER INC.$50,346Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-11-05PFIZER INC.$17,000Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-10-31PFIZER INC.$44,181Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-10-31PFIZER INC.$33,467Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-10-30PFIZER INC.$39,010Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-10-30PFIZER INC.$1,642Research paymentCash or cash equivalentTALZENNA Drug, ONCOLOGYA PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB IN COMBINATION WITH PHYSICIANS CHOICE OF ENZALUT2020
2020-10-29PFIZER INC.$2,607Research paymentCash or cash equivalentA PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF066512020
2020-10-28PFIZER INC.$5,655Research paymentCash or cash equivalentA LONGTERM OPEN LABEL EXTENSION STUDY OF PF06651600 FOR THE TREATMENT OF ALOPECIA AREATA2020
2020-10-26MEDIVATION LLC.$9,210Research paymentCash or cash equivalentTALZENNA Drug, ONCOLOGYA PHASE 3 OPENLABEL RANDOMIZED PARALLEL2ARMMULTICENTER STUDY OF TALAZOPARIBBMN 673 VERSUS PHYSICIANS CHOICE IN GERMLINE 2020
2020-10-23PFIZER INC.$118,813Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-10-23PFIZER INC.$46,291Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-10-22PFIZER INC.$45,188Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-10-16PFIZER INC.$1,642Research paymentCash or cash equivalentTALZENNA Drug, ONCOLOGYA PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB IN COMBINATION WITH PHYSICIANS CHOICE OF ENZALUT2020
2020-10-14PFIZER INC.$57,552Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-10-10PFIZER INC.$63,215Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-10-08PFIZER INC.$2,400Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-10-07PFIZER INC.$50,570Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-10-06PFIZER INC.$65,971Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-10-02PFIZER INC.$147,864Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-10-02PFIZER INC.$129,306Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-10-02PFIZER INC.$4,262Research paymentCash or cash equivalentA PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF066512020
2020-10-01PFIZER INC.$158,301Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-10-01PFIZER INC.$145,509Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-10-01PFIZER INC.$127,920Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-10-01PFIZER INC.$110,331Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-10-01PFIZER INC.$107,932Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-10-01PFIZER INC.$99,937Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-10-01PFIZER INC.$58,395Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-10-01PFIZER INC.$12,655Research paymentCash or cash equivalentTALZENNA Drug, ONCOLOGYA PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB IN COMBINATION WITH PHYSICIANS CHOICE OF ENZALUT2020
2020-10-01PFIZER INC.$2,037Research paymentCash or cash equivalentA LONGTERM OPEN LABEL EXTENSION STUDY OF PF06651600 FOR THE TREATMENT OF ALOPECIA AREATA2020
2020-09-28PFIZER INC.$560Research paymentCash or cash equivalentLORBRENA Drug, ONCOLOGYATOPIC DERMATITIS STANDING COHORT USING A COHORT OF KAISER PERMANENTE NORTHERN CALIFORNIA MEMBERS KPNC2020
2020-09-26PFIZER INC.$116,577Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-09-26PFIZER INC.$92,077Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-09-25PFIZER INC.$49,824Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-09-19PFIZER INC.$193,390Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-09-19PFIZER INC.$116,959Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-09-19PFIZER INC.$3,230Research paymentCash or cash equivalentTALZENNA Drug, ONCOLOGYA PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB IN COMBINATION WITH PHYSICIANS CHOICE OF ENZALUT2020
2020-09-18PFIZER INC.$86,713Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-09-18PFIZER INC.$2,581Research paymentCash or cash equivalentA PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF066512020
2020-09-17PFIZER INC.$871Research paymentCash or cash equivalentA LONGTERM OPEN LABEL EXTENSION STUDY OF PF06651600 FOR THE TREATMENT OF ALOPECIA AREATA2020
2020-09-12PFIZER INC.$130,549Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-09-11PFIZER INC.$69,979Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-09-10PFIZER INC.$83,461Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-09-07PFIZER INC.$15,956Research paymentCash or cash equivalentCLINICAL CHARACTERISTICS TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH HRHER2 BREAST CANCER IN THE UNITED STATES2020
2020-08-29PFIZER INC.$80,932Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-08-29PFIZER INC.$2,607Research paymentCash or cash equivalentA PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF066512020
2020-08-22PFIZER INC.$20,233Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-08-19PFIZER INC.$5,938Research paymentCash or cash equivalentA PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF066512020
2020-08-18PFIZER INC.$5,359Research paymentCash or cash equivalentA LONGTERM OPEN LABEL EXTENSION STUDY OF PF06651600 FOR THE TREATMENT OF ALOPECIA AREATA2020
2020-08-13PFIZER INC.$6,491Research paymentIn-kind items and servicesA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-08-12PFIZER INC.$2,375Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-08-10PFIZER INC.$148,632Research paymentCash or cash equivalentLORBRENA Drug, ONCOLOGYATOPIC DERMATITIS STANDING COHORT USING A COHORT OF KAISER PERMANENTE NORTHERN CALIFORNIA MEMBERS KPNC2020
2020-08-08PFIZER INC.$10,175Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-07-31PFIZER INC.$1,361Research paymentCash or cash equivalentA LONGTERM OPEN LABEL EXTENSION STUDY OF PF06651600 FOR THE TREATMENT OF ALOPECIA AREATA2020
2020-07-31PFIZER INC.$1,066Research paymentCash or cash equivalentA PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF066512020
2020-07-31PFIZER INC.$897Research paymentCash or cash equivalentTALZENNA Drug, ONCOLOGYA PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB IN COMBINATION WITH PHYSICIANS CHOICE OF ENZALUT2020
2020-07-30PFIZER INC.$3,500Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-07-29PFIZER INC.$1,920Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-07-27PFIZER INC.$74,712Research paymentCash or cash equivalentLORBRENA Drug, ONCOLOGYATOPIC DERMATITIS STANDING COHORT USING A COHORT OF KAISER PERMANENTE NORTHERN CALIFORNIA MEMBERS KPNC2020
2020-07-23PFIZER INC.$14,000Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-07-17PFIZER INC.$4,183Research paymentCash or cash equivalentA PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF066512020
2020-07-17PFIZER INC.$1,538Research paymentCash or cash equivalentA PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF066512020
2020-07-02PFIZER INC.$215,260Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-07-02PFIZER INC.$11,329Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-07-02PFIZER INC.$3,068Research paymentCash or cash equivalentA LONGTERM OPEN LABEL EXTENSION STUDY OF PF06651600 FOR THE TREATMENT OF ALOPECIA AREATA2020
2020-06-25PFIZER INC.$2,400Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYA RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS2020
2020-06-24PFIZER INC.$960Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-06-16PFIZER INC.$5,798Research paymentCash or cash equivalentA PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF066512020
2020-06-15PFIZER INC.$1,200Research paymentCash or cash equivalentPREVNAR 13 Biological, VACCINESCRCCONTINUATION OF ASSESSMENT OF THE IMPACT OF PREVNAR 13 13VPNC ON INVASIVE PNEUMOCOCCAL DISEASE CAUSED BY VACCINE SERO2020
2020-06-11PFIZER INC.$9,177Research paymentCash or cash equivalentPREVNAR 13 Biological, VACCINESA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V2020
2020-06-11PFIZER INC.$6,119Research paymentCash or cash equivalentPREVNAR 13 Biological, VACCINESA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V2020
2020-06-11PFIZER INC.$5,189Research paymentCash or cash equivalentPREVNAR 13 Biological, VACCINESA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V2020
2020-06-11PFIZER INC.$4,250Research paymentCash or cash equivalentPREVNAR 13 Biological, VACCINESA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V2020
2020-06-04PFIZER INC.$128,602Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-06-04PFIZER INC.$71,098Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-06-04PFIZER INC.$66,373Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-06-04PFIZER INC.$66,317Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-06-04PFIZER INC.$56,575Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-06-04PFIZER INC.$50,145Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-06-04PFIZER INC.$47,861Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-06-04PFIZER INC.$44,173Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-06-04PFIZER INC.$4,354Research paymentCash or cash equivalentTRUMENBA Biological, VACCINESA PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED STUDY TO ASSESS THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF BIVA2020
2020-06-04PFIZER INC.$960Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-05-29PFIZER INC.$10,173Research paymentCash or cash equivalentA PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF066512020
2020-05-27PFIZER INC.$1,200Research paymentCash or cash equivalentPREVNAR 13 Biological, VACCINESA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V2020
2020-05-16PFIZER INC.$4,237Research paymentCash or cash equivalentA PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF066512020
2020-05-15PFIZER INC.$5,129Research paymentCash or cash equivalentA LONGTERM OPEN LABEL EXTENSION STUDY OF PF06651600 FOR THE TREATMENT OF ALOPECIA AREATA2020
2020-05-14PFIZER INC.$10,806Research paymentCash or cash equivalentPREVNAR 13 Biological, VACCINESA PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACC2020
2020-05-14PFIZER INC.$1,500Research paymentCash or cash equivalentTRUMENBA Biological, VACCINESA PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED STUDY TO ASSESS THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF BIVA2020
2020-05-14PFIZER INC.$1,200Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-05-14PFIZER INC.$650Research paymentCash or cash equivalentTRUMENBA Biological, VACCINESA PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED STUDY TO ASSESS THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF BIVA2020
2020-05-13PFIZER INC.$5,050Research paymentCash or cash equivalentPREVNAR 13 Biological, VACCINESA PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACC2020
2020-05-07PFIZER INC.$8,400Research paymentCash or cash equivalentPREVNAR 13 Biological, VACCINESA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V2020
2020-05-07PFIZER INC.$1,500Research paymentCash or cash equivalentPREVNAR 13 Biological, VACCINESA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V2020
2020-05-07PFIZER INC.$650Research paymentCash or cash equivalentPREVNAR 13 Biological, VACCINESA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V2020
2020-05-01PFIZER INC.$8,267Research paymentCash or cash equivalentPREVNAR 13 Biological, VACCINESA PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJ2020
2020-05-01PFIZER INC.$7,727Research paymentCash or cash equivalentPREVNAR 13 Biological, VACCINESA PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJ2020
2020-05-01PFIZER INC.$5,540Research paymentCash or cash equivalentPREVNAR 13 Biological, VACCINESA PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJ2020
2020-05-01PFIZER INC.$3,974Research paymentCash or cash equivalentA PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF066512020
2020-04-30PFIZER INC.$5,571Research paymentCash or cash equivalentPREVNAR 13 Biological, VACCINESA PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJ2020
2020-04-30PFIZER INC.$2,607Research paymentCash or cash equivalentTALZENNA Drug, ONCOLOGYA PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB IN COMBINATION WITH PHYSICIANS CHOICE OF ENZALUT2020
2020-04-22PFIZER INC.$3,889Research paymentCash or cash equivalentA PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF066512020
2020-04-22PFIZER INC.$2,204Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-04-22PFIZER INC.$1,920Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-04-22PFIZER INC.$1,185Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-04-22PFIZER INC.$629Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-04-22PFIZER INC.$500Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-04-22PFIZER INC.$400Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-04-22PFIZER INC.$314Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-04-22PFIZER INC.$200Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-04-21PFIZER INC.$8,396Research paymentCash or cash equivalentA LONGTERM OPEN LABEL EXTENSION STUDY OF PF06651600 FOR THE TREATMENT OF ALOPECIA AREATA2020
2020-04-18PFIZER INC.$2,607Research paymentCash or cash equivalentTALZENNA Drug, ONCOLOGYA PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB IN COMBINATION WITH PHYSICIANS CHOICE OF ENZALUT2020
2020-04-13PFIZER INC.$185,988Research paymentCash or cash equivalentLORBRENA Drug, ONCOLOGYATOPIC DERMATITIS STANDING COHORT USING A COHORT OF KAISER PERMANENTE NORTHERN CALIFORNIA MEMBERS KPNC2020
2020-04-08PFIZER INC.$2,880Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-04-08PFIZER INC.$600Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-04-08PFIZER INC.$300Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-03-30PFIZER INC.$148,632Research paymentCash or cash equivalentLORBRENA Drug, ONCOLOGYATOPIC DERMATITIS STANDING COHORT USING A COHORT OF KAISER PERMANENTE NORTHERN CALIFORNIA MEMBERS KPNC2020
2020-03-26PFIZER INC.$3,260Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-03-26PFIZER INC.$1,259Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-03-26PFIZER INC.$629Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-03-26PFIZER INC.$314Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-03-19PFIZER INC.$17,771Research paymentCash or cash equivalentA PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF066512020
2020-03-18PFIZER INC.$1,200Research paymentCash or cash equivalentPREVNAR 13 Biological, VACCINESA PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJ2020
2020-03-17PFIZER INC.$1,022Research paymentCash or cash equivalentPREVNAR 13 Biological, VACCINESA PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACC2020
2020-03-12PFIZER INC.$2,400Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-03-12PFIZER INC.$1,259Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-03-12PFIZER INC.$1,185Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-03-12PFIZER INC.$629Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-03-12PFIZER INC.$500Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-03-12PFIZER INC.$314Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-03-12PFIZER INC.$314Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-03-12PFIZER INC.$314Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-03-12PFIZER INC.$250Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-03-05PFIZER INC.$944Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-03-05PFIZER INC.$629Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-03-05PFIZER INC.$629Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-03-05PFIZER INC.$314Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-03-05PFIZER INC.$314Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-02-28PFIZER INC.$11,858Research paymentCash or cash equivalentPREVNAR 13 Biological, VACCINESA PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJ2020
2020-02-28PFIZER INC.$8,650Research paymentCash or cash equivalentA LONGTERM OPEN LABEL EXTENSION STUDY OF PF06651600 FOR THE TREATMENT OF ALOPECIA AREATA2020
2020-02-26PFIZER INC.$3,304Research paymentCash or cash equivalentA PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF066512020
2020-02-25PFIZER INC.$2,093Research paymentCash or cash equivalentPREVNAR 13 Biological, VACCINESA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V2020
2020-02-25PFIZER INC.$1,256Research paymentCash or cash equivalentPREVNAR 13 Biological, VACCINESA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V2020
2020-02-25PFIZER INC.$1,256Research paymentCash or cash equivalentPREVNAR 13 Biological, VACCINESA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V2020
2020-02-25PFIZER INC.$837Research paymentCash or cash equivalentPREVNAR 13 Biological, VACCINESA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V2020
2020-02-25PFIZER INC.$592Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-02-20PFIZER INC.$4,090Research paymentCash or cash equivalentPREVNAR 13 Biological, VACCINESA PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACC2020
2020-02-19PFIZER INC.$4,723Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-02-19PFIZER INC.$3,853Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-02-19PFIZER INC.$1,889Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-02-19PFIZER INC.$1,574Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-02-19PFIZER INC.$1,259Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-02-19PFIZER INC.$1,259Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-02-19PFIZER INC.$629Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-02-19PFIZER INC.$629Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-02-19PFIZER INC.$629Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-02-19PFIZER INC.$629Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-02-19PFIZER INC.$314Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-02-13PFIZER INC.$14,981Research paymentCash or cash equivalentLORBRENA Drug, ONCOLOGYAN EXPANDED ACCESS PROTOCOL FOR LORLATINIB FOR TREATMENT OF PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER HARBORING S2020
2020-02-13PFIZER INC.$2,667Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-02-06PFIZER INC.$2,093Research paymentCash or cash equivalentPREVNAR 13 Biological, VACCINESA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V2020
2020-02-06PFIZER INC.$1,920Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-02-06PFIZER INC.$1,778Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020
2020-02-06PFIZER INC.$1,259Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2020

The latest 200 records of 241.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Contra Costa CountyAntioch city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Antioch, CA, county Contra Costa County, CA, state California; placed by its city name.

MeasurePlace (city or town)
Antioch, CA
County
Contra Costa County, CA
State
California
Population B01003116,4771,165,01239,287,377
Population, 2020 census P1115,2911,165,92739,538,223
Median age B0100238.440.537.9
Under 18 B0100122.8%22.0%22.0%
65 and over B0100114.3%17.1%15.7%
Households B1100137,381414,41713,548,091
Foreign born B0500224.6%26.6%27.0%
Median household income B19013$97,465$127,229$99,122
Median family income B19113$109,115$148,679$113,346
Per capita income B19301$41,008$62,927$49,513
Poverty rate B1700111.4%8.4%12.0%
Unemployment rate B230257.4%6.5%6.6%
Civilian labor force B2302560,709608,62020,068,466
Mean commute (minutes) B0801342.035.328.7
Bachelor's degree or higher B1500323.9%45.2%37.1%
Housing units B2500138,629429,26014,644,735
Owner-occupied B2500363.6%68.0%55.9%
Renters B2500336.4%32.0%44.1%
Median home value B25077$629,700$866,800$734,700
Median gross rent B25064$2,278$2,375$2,036
White, not Hispanic B0300223.4%38.1%33.8%
Black B0300218.2%7.9%5.2%
Hispanic or Latino B0300235.6%27.6%40.2%
Asian B0300213.9%18.6%15.3%
American Indian and Alaska Native B030020.5%0.2%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.1% in Sep 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Antioch, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.